Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ganciclovir sodium
Drug ID BADD_D01004
Description An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Indications and Usage For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Marketing Status approved; investigational
ATC Code S01AD09; J05AB06
DrugBank ID DB01004
KEGG ID D04301
MeSH ID D015774
PubChem ID 23700083
TTD Drug ID D05ARP
NDC Product Code 46014-1054; 70436-089; 25021-185; 63323-315; 0143-9299; 51817-171; 0004-6941
UNII 02L083W284
Synonyms Ganciclovir | Gancyclovir | BW-759 | Ganciclovir Sodium | Ganciclovir, Monosodium Salt | RS-21592 | BIOLF-62 | Cytovene
Chemical Information
Molecular Formula C9H12N5NaO4
CAS Registry Number 84245-13-6
SMILES C1=NC2=C(N1COC(CO)CO)N=C(N=C2[O-])N.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stevens-Johnson syndrome23.03.01.007; 10.01.01.045; 12.03.01.014; 11.07.01.005--
Testicular failure21.13.01.004; 05.05.02.001--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Torsade de pointes02.03.04.005--Not Available
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis10.02.02.006; 24.12.04.027--
Ventricular tachycardia02.03.04.010--
Visual impairment06.02.10.013--Not Available
Vitreous disorder06.08.03.006--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Vasodilation procedure25.03.01.001--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Foetal disorder18.03.02.001--Not Available
Haematotoxicity12.03.01.025; 01.05.01.007--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Psychotic disorder19.03.01.002--
Renal impairment20.01.03.010--Not Available
Gene mutation03.20.03.001--Not Available
Device related infection11.01.08.018; 08.07.01.005--
Bone marrow failure01.03.03.005--
Device related sepsis11.01.11.008; 08.07.01.004--Not Available
Candida infection11.03.03.021--
Multiple organ dysfunction syndrome08.01.03.057--
The 5th Page    First    Pre   5    Total 5 Pages